A Phase 1/2 Dose Escalation and Expansion Study of Sonodynamic Therapy With SONALA-001 in Combination With Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects With Progressive or Recurrent Glioblastoma Multiforme (rGBM)
Latest Information Update: 29 Jul 2024
Price :
$35 *
At a glance
- Drugs Aminolevulinic acid (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors SonALAsense
- 26 Jul 2024 Status changed from active, no longer recruiting to discontinued to funding challenges and not due to safety concerns.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 13 Feb 2024 Status changed from recruiting to active, no longer recruiting.